2. Academic Validation
  3. Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer

Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer

  • Nat Genet. 2025 Oct;57(10):2468-2481. doi: 10.1038/s41588-025-02336-6.
Jie Luo # 1 2,  Zhixiang Chen # 3 4 5,  Yuanyuan Qiao # 1 2 3,  Jean Ching-Yi Tien 1 2,  Eleanor Young 1,  Rahul Mannan 1 2,  Somnath Mahapatra 1 2,  Rupam Bhattacharyya 1 2,  Lanbo Xiao 1 2,  Tongchen He 1 2,  Sanjana Eyunni 1 2 6,  Yuping Zhang 1 2,  Yang Zheng 1 2,  Fengyun Su 1 2,  Xuhong Cao 1 2 7,  Rui Wang 1 2,  Yunhui Cheng 1 2,  Rithvik Seri 1,  James George 1,  Miriam Shahine 1,  Stephanie J Miner 1 2,  Matthew G Rees 8,  Melissa M Ronan 8,  Jennifer A Roth 8,  Ulka Vaishampayan 3 4,  Mi Wang 3 4 9 10,  Shaomeng Wang 11 12 13 14,  Abhijit Parolia 15 16 17 18,  Arul M Chinnaiyan 19 20 21 22 23
Affiliations

Affiliations

  • 1 Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
  • 2 Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
  • 3 Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
  • 4 Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
  • 5 Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.
  • 6 Molecular and Cellular Pathology Program, University of Michigan, Ann Arbor, MI, USA.
  • 7 Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI, USA.
  • 8 Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • 9 Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA.
  • 10 Department of Medicinal Chemistry, University of Michigan, Ann Arbor, MI, USA.
  • 11 Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA. shaomeng@med.umich.edu.
  • 12 Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. shaomeng@med.umich.edu.
  • 13 Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA. shaomeng@med.umich.edu.
  • 14 Department of Medicinal Chemistry, University of Michigan, Ann Arbor, MI, USA. shaomeng@med.umich.edu.
  • 15 Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA. aparolia@umich.edu.
  • 16 Department of Pathology, University of Michigan, Ann Arbor, MI, USA. aparolia@umich.edu.
  • 17 Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA. aparolia@umich.edu.
  • 18 Department of Urology, University of Michigan, Ann Arbor, MI, USA. aparolia@umich.edu.
  • 19 Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA. arul@umich.edu.
  • 20 Department of Pathology, University of Michigan, Ann Arbor, MI, USA. arul@umich.edu.
  • 21 Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA. arul@umich.edu.
  • 22 Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI, USA. arul@umich.edu.
  • 23 Department of Urology, University of Michigan, Ann Arbor, MI, USA. arul@umich.edu.
  • # Contributed equally.
PMID: 41044247 DOI: 10.1038/s41588-025-02336-6
Abstract

Prostate Cancer is driven by oncogenic transcription factor enhanceosomes comprising chromatin and epigenetic regulators. The lysine acetyltransferases p300 and CREB-binding protein (CBP) are key cofactors that activate enhancers through histone acetylation. Here we identify p300/CBP-mediated multisite histone H2B N-terminal acetylation (H2BNTac) as a defining feature of oncogenic enhanceosomes in Androgen Receptor (AR)-positive prostate Cancer. p300/CBP are essential for AR and ETS transcription factor ERG transcriptional activity, and their dual degradation eliminates H2BNTac and histone H3 lysine 27 acetylation at hyperactive enhancers, leading to stronger suppression of oncogenic transcription than targeting either paralog or bromodomain alone. Cytotoxicity profiling across >900 cell lines revealed that tumors with high H2BNTac, including AR-positive prostate Cancer, are selectively dependent on p300/CBP. In preclinical models, systemic p300/CBP degradation inhibited tumor growth, synergized with AR antagonists and showed no evident toxicity. These findings position H2BNTac as an epigenetic marker of enhancer addiction and establish dual p300/CBP degradation as a promising therapeutic strategy for enhancer-driven cancers.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z